I read with interest the paper by Lichtenstein et al. on factors associated with the development of strictures in Crohn’s disease (CD). The authors’ observations, based on the TREAT registry and the ACCENT I study, indicate that CD severity and duration, ileal disease, and new corticosteroid use—but not infliximab therapy—are associated with a greater risk of developing strictures. The latter observation, in particular, runs against previous results, which might have been affected by unadjusted analyses. Taken together with other data showing an antifibrogenic effect of infliximab in CD, the Lichtenstein et al. paper suggests, inter alia, that infliximab should be given earlier in the course of disease, before collagen deposition has begun.
Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease
SORRENTINO, Dario Rosario
2006-01-01
Abstract
I read with interest the paper by Lichtenstein et al. on factors associated with the development of strictures in Crohn’s disease (CD). The authors’ observations, based on the TREAT registry and the ACCENT I study, indicate that CD severity and duration, ileal disease, and new corticosteroid use—but not infliximab therapy—are associated with a greater risk of developing strictures. The latter observation, in particular, runs against previous results, which might have been affected by unadjusted analyses. Taken together with other data showing an antifibrogenic effect of infliximab in CD, the Lichtenstein et al. paper suggests, inter alia, that infliximab should be given earlier in the course of disease, before collagen deposition has begun.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
